bluebird bio Inc BLUE:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/18/24 EDT
0.95UNCH (UNCH)
Volume
35,207
Close
0.953UNCH (UNCH)
Volume
6,477,233
52 week range
0.88 - 5.53
Loading...
  • Open0.965
  • Day High1.01
  • Day Low0.92
  • Prev Close0.953
  • 52 Week High5.53
  • 52 Week High Date12/08/23
  • 52 Week Low0.88
  • 52 Week Low Date02/06/24

Key Stats

  • Market Cap181.409M
  • Shares Out190.36M
  • 10 Day Average Volume5.08M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change-30.94

KEY STATS

  • Open0.965
  • Day High1.01
  • Day Low0.92
  • Prev Close0.953
  • 52 Week High5.53
  • 52 Week High Date12/08/23
  • 52 Week Low0.88
  • 52 Week Low Date02/06/24
  • Market Cap181.409M
  • Shares Out190.36M
  • 10 Day Average Volume5.08M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change-30.94

RATIOS/PROFITABILITY

  • EPS (TTM)-0.74
  • P/E (TTM)-1.28
  • Fwd P/E (NTM)-0.50
  • EBITDA (TTM)-326.704M
  • ROE (TTM)-47.81%
  • Revenue (TTM)21.726M
  • Gross Margin (TTM)-10.08%
  • Net Margin (TTM)-419.62%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On bluebird bio Inc

 

Profile

MORE
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene...
Mark Vachon
Independent Chairman of the Board
Andrew Obenshain
President, Chief Executive Officer, Director
Thomas Klima
Chief Commercial and Operating Officer
Christopher Krawtschuk CPA
Chief Financial Officer
Address
455 Grand Union Boulevard
Somerville, MA
02145
United States

Top Peers

SYMBOLLASTCHG%CHG
HOWL
Werewolf Therapeutics Inc
5.87UNCHUNCH
ZVRA
Zevra Therapeutics Inc
4.50UNCHUNCH
CAPR
Capricor Therapeutics Inc
5.05UNCHUNCH
CLLS
Cellectis SA
2.47UNCHUNCH
PRQR
ProQR Therapeutics NV
1.86UNCHUNCH